BridgeMD
A Phase 2 Study of CRD-4730 in CPVT
EU CTIS ID: 2022-502845-83-00
What this study is testing
To assess the safety and tolerability of CRD-4730 when administered to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The participant is male or female ≥18 years of age
- The participant has a confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the investigator and documented in the study source records.
- The participant can perform an EST during which frequent premature ventricular contractions (PVCs) (≥10 per minute), ventricular bigeminy; or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator. Please refer to the complete VA scoring system, as described in Section 8.4.2.
- The participant has been on a stable dose of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to Screening.
- The patient must be willing to adhere to all contraceptive requirements.
You likely can't join if
- The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
- The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.
- The participant has a history of malignancy within the past 5 years at Screening, with the exception of successfully treated basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin or cervical carcinoma in situ.
- The female participant is pregnant, lactating/breastfeeding, or has plans to become pregnant during the study or within 3 months following the last study drug administration.
- Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.
The study team makes the final eligibility decision.
Where it's taking place
- United States
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States; Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.